Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
4.330
-0.060 (-1.37%)
At close: May 9, 2025, 4:00 PM
4.330
0.00 (0.00%)
After-hours: May 9, 2025, 7:59 PM EDT
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenue of $14.75M in the quarter ending March 31, 2025, with 6.89% growth. This brings the company's revenue in the last twelve months to $59.79M, up 29.32% year-over-year. In the year 2024, Recursion Pharmaceuticals had annual revenue of $58.84M with 32.00% growth.
Revenue (ttm)
$59.79M
Revenue Growth
+29.32%
P/S Ratio
22.88
Revenue / Employee
$74,738
Employees
800
Market Cap
1.76B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
RXRX News
- 4 days ago - Recursion to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 days ago - Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Recursion Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 days ago - Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings - Seeking Alpha
- 5 days ago - Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden - GlobeNewsWire
- 12 days ago - Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th - GlobeNewsWire
- 17 days ago - Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 - GlobeNewsWire
- 24 days ago - HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data - PRNewsWire